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Parenchymal lung diseases are the main cause of persistent pulmonary hypertension of the newborn (PPHN). We aimed to assess
the non cardiac conditions associated to PPHN in the newborn and the survival rate over the last 15 years, at our center. A
retrospective chart review of the neonates admitted for PPHN from 1996 to 2010 was performed. New therapies were introduced
in2003,andthesurvivalratesbetweentwoperiods(1996–2002and2003–2010)werecompared.Outof6750newborns,78(1.1%)
had the diagnosis of PPHN of non cardiac cause. The most prevalent causes were associated to pulmonary hypoplasia (30.7%),
infection (24.3%), and aspiration syndromes (15.3%). Many other causes were identiﬁed in 33.3%. The overall survival rate was
68%. There was a signiﬁcant diﬀerence on survival rates between the two periods (1996–2002 = 63.8% and 2003–2010 = 71.4%,
P = 0.04). Our study showed a myriad of non cardiac aetiologies for PPHN of the newborn, most of them related to lung disease
or lung hypoplasia. We observed an improvement in survival rate since 2003, which was associated to the use of new therapies.
1.Introduction
From the ﬁrst clinical classiﬁcation of pulmonary hyper-
tension (PH), in Evian (France) in 1973, the knowledge
about the disease signiﬁcantly improved and recently, in
2008, that classiﬁcation was updated at Dana Point (USA)
[1]. This classiﬁcation tries to include all possible causes of
PH in children and adults; nevertheless, it is not a speciﬁc
classiﬁcation for PH presenting in the newborn.
PH presenting in the neonatal period may result from
am y r i a do fc a u s e s[ 2]. Most commonly, it presents imme-
diately after birth, a condition referred to as persistent
pulmonary hypertension of the newborn (PPHN), when
pulmonary vascular resistance fails to decrease at birth.
This disease is recognized as arterial PH in the Dana Point
classiﬁcation of PH. Most cases of PPHN are associated with
lung parenchymal diseases, such as meconium aspiration
syndrome,andrespiratorydistresssyndrome;however,some
presentwithoutknownlungdiseaseasprimaryPPHN.Some
infants who have PPHN have lethal causes of respiratory fail-
ure,suchasalveolar-capillarydysplasia [3],genetic defectsin
surfactant synthesis [4], or severe lung hypoplasia secondary
to oligohydramnios or congenital anomalies. Congenital
heart diseases are also a possible cause of PH, but usually the
prognosis and outcome are more related to the heart disease
than to the pulmonary vascular involvement during the ﬁrst
weeks of life. In a new group of newborns, PH presents
without known heart or lung disease, as primary PPHN.
Over the last decades, a timely referral to a tertiary
centre, the use of new techniques of mechanical ventilation,
extracorporeal membrane oxygenation, a better support
therapy, the use of inhaled nitric oxide (iNO), and new
pharmacological pulmonary vasodilators have ameliorated
the prognosis of this clinical condition allowing a survival
rate of about 90% in several referral centres [5].
The aims of this study were to review the non cardiac
conditions associated to PPHN in the newborn and the
survival rate of the aﬀected patients over the last 15 years,
at our centre.2 Pulmonary Medicine
2.MaterialandMethods
Neonates with the diagnosis of PPHN of non cardiac
cause, admitted between 1996 and 2010, were identiﬁed
from the database of our neonatal intensive care unit
(NICU), a tertiary referral center for neonatal cardiac and
pediatric surgery in the north of Portugal. Gestational data,
demographic data, the cause of PPHN, treatment, days of
NICU stay, neonatal outcome, and necropsy ﬁndings of the
deceased neonates wereretrieved from the clinical charts and
retrospectively reviewed.
The diagnosis of PPHN was made on clinical grounds,
chest X-ray, arterial blood gases analysis, and 2D-echocar-
diograhic ﬁndings. Pulmonary artery pressure estimation
was based on the gradient between right ventricle and
atrium, through tricuspid regurgitation, assuming the right
atrium pressure as 15mmHg (estimated pulmonary systolic
artery pressure (PSAP) = right ventricle to right atrium
gradient + 15mmHg).
The diagnosis of PPHN was made on clinical grounds,
chest X-ray, arterial blood gases analysis, and 2D-echocardi-
ograhic ﬁndings. Pulmonary artery pressure estimation was
based on the gradient between right ventricle and atrium,
through tricuspid regurgitation, assuming the right atrium
pressure as 10mmHg (estimated pulmonary systolic artery
pressure (PSAP) = right ventricle to right atrium gradient
+ 15mmHg). Pulmonary hypertension was stratiﬁed as
mild if estimated PSAP was less than 40mmHg, moderate
if between 40 and 60mmHg, and severe if higher than
60mmHg. Additionally, other parameters were evaluated
to help in deﬁnition of the severity of PH: (i) shunt
direction at ductus arteriosus or foramen ovale (left-to-
right shunt was considered normal, bidireccional shunt was
considered sign of mild to moderate PH and right to left
shunt was considered sign of severe PH); (ii) orientation of
ventricular septum (the normal orientation was considered
left to right, septum rectiﬁcation was indicative of mild-to-
moderate PH, and when the septum budge from right-to-
left a severe PH was likely), and (iii) systolic function of the
left ventricle, through the left ventricular ejection fraction
(in cases of moderate PH it was expected a hipercontractil
left ventricle whilst in severe PH usually we found a decrease
on left ventricle ejection fraction). All the parameters were
evaluated routinely. Echocardiographic evaluation was also
used to exclude or conﬁrm any congenital heart disease.
Inhalednitricoxide(iNO)(usuallystartingwith20ppm)
has been routinely used since 2003 after echocardiographic
deﬁnition of severe PH and an oxygenation index (mean
airway pressure × fraction of inspired oxygen × 100/partial
arterial pressure of oxygen) over 20. Sildenaﬁl has been used
ininfantswithpersistentpulmonaryhypertensionrefractory
to iNO. Since iNO and sildenaﬁl have been used since 2003,
a comparison of the survival rates between two epochs was
made (1996–2002 and 2003–2010).
Since 2003, we have also routinely used a total daily water
intake of 80mL/kg (until start enteral feeds) along with a
perfusion of dopamine 5mcg/kg/min, in order to keep a
systemic blood pressure over 40mmHg, and a hematocrit
of about 45% (haemoglobin ≥15g/dL). A perfusion of
Table 1: Demographics (n = 78).
Gestational age (weeks), median (min–max) 39 (30–41)
Preterm (<37 weeks gestation) 16 (20.5%)
Birthweight (grams), median (min–max) 3080 (1450–4170)
Intrauterine growth restriction 4 (5%)
Gender
male 53 (67.9%)
female 25 (32.1%)
C-section 51 (65.3%)
Outborn 34 (43.5%)
dobutamine (5mcg/kg/min) is started if signs of myocardial
dysfunction are present at echocardiographic evaluation.
Higher doses of dopamine and dobutamine or epinephrine
perfusion are used according to clinical criteria. Minimal
stimulation as well as sedation and analgesia is usually
performed with a perfusion of morphine (or fentanyl in
the case of hypotension) and midazolam. Paralyzing agents
as vecuronium are usually avoided; it is only used in
selected cases as a rescue ventilation adjunt therapy. When
mechanical ventilation is need, conventional ventilation is
preferred to high-frequency oscillation ventilation, which is
mainly used as rescue ventilation. The goals of mechanical
ventilation are to maintain a PaO2 of 60–90mmHg and a
PaCO2 >30mmHg (usually 35–50mmHg), in order to avoid
oxidative stress and hypocapnia.
ECMO treatment was not achievable in our country
until 2010. Our centre, recently, started ECMO support to
neonates and children.
Categorical variables were compared through Chi-square
ortheexactFisher’s test.TheMann-Whitneytestwasusedto
compare two independent samples.
This study has been approved by the ethics committee
b o a r do fo u ri n s t i t u t i o n .
3. Results
In the last 15 years, 6750 newborns were admitted to our
unit.Seventy-eight(1.1%)hadthediagnosisofPPHNofnon
cardiac cause. The demographics of the studied population
are reported in Table 1, and the causes of PPHN are reported
in Table 2. Twenty-ﬁve (32.0%) were deceased (13 males; 12
females). The median of death day was 7 (1–114). There
were 34 outborns that were referred to our centre. Mortality
rate in the outborn group was 32.3% (11/34), not diﬀerent
from the inborn group that was 31.8% (14/44) (P = 0.967).
Pulmonary hypertension was classiﬁed as mild in 14 (17.9%)
patients, moderate in 24 (30.7%), and severe in 40 (51.2%).
TreatmentaspectsarereportedinTable 3.Thenormalization
of pulmonary hypertension occurred by day eight of life (2–
160)inthesurvivors.ThemedianofdaysofstayintheNICU
was12days(1–167).Theoverallsurvivalratewas68%.There
was a signiﬁcant diﬀerence on survival rates between two
periods (1996–2002 = 63.8% and 2003–2010 = 71.4%) (P =
0.04); see Table 4. Along with this increase in survival, days
of NICU stay and of normalization of PH in the survivors
accordingly increased.Pulmonary Medicine 3
Table 2: Causes of PPHN (n = 78).
Aspiration of bloody amniotic ﬂuid, n (%) 1 (1.2)
Aspiration of blood from upper airways 1 (1.2)
(traumatic intubation), n (%)
Meconium aspiration syndrome, n (%) 10 (12.8) (2†)
Congenital pneumonia and sepsis, n (%) 19 (24.3) (4†)
Severe hyaline membrane disease, n (%) 3 (3.8) (1†)
Transient tachypnea of the newborn, n (%) 4 (5.1)
Intrauterine ductus arteriosus closure 2 (2.5)
(indomethacin), n (%)
Congenital diaphragmatic hernia, n (%) 17 (21.7) (10†)
Potter syndrome, n (%) 1 (1.2) (1†)
Nephrourological malformation with 1 (1.2)
oligoamnios, n (%)
Idiopathic hypoplastic lung, n (%) 2 (2.5) (1†)
Idiopathic pulmonary arteriolar 1 (1.2) (1†)
calciﬁcation, n (%)
Pulmonary “arteriopathy”, n (%) 1 (1.2) (1†)
Arterial pulmonary thrombosis, n (%) 1 (1.2) (1†)
Fetal tachyarrhythmia, n (%) 1 (1.2)
Maternal diabetes, n (%) 1 (1.2) (1†)
Malformation of vein of Galeno, n (%) 2 (2.5) (2†)
Perinatal asphyxia, n (%) 4 (5.1)
Unknown aetiology, n (%) 6 (7.6)
†:d e c e a s e d .
Table 3: Treatment (n = 78).
Inhaled nitric oxide, n (%) 19 (24.3%)
Surfactant, n (%) 24 (30.7%)
Dopamine, n (%) 57 (73%)
Dobutamine, n (%) 35 (44.8%)
Epinephrine, n (%) 3 (3.8%)
Sildenaﬁl, n (%) 12 (15.3%)
Diuretics, n (%) 33 (42.3%)
Sedation, n (%) 71 (91%)
Oxygen, n (%) 78 (100%)
Days of oxygen, median (min–max) 6 (1–114)
Mechanical ventilation, n (%) 71 (91%)
Days of mechanical ventilation, median (min–max) 7 (1–114)
Extracorporeal membrane 1 (1.2%)
oxygenation (ECMO), n (%)
Days of ECMO 17
4. Discussion
Persistenceofpulmonaryhypertensionleadingtorespiratory
failure in the neonate has been recognized for 40 years since
its original description by Gersony and colleagues in 1969
[6]. During the development of the pulmonary vasculature
in the fetus, many structural and functional changes occur
to prepare the lung for the transition to air breathing. The
developmentofthepulmonarycirculationisgeneticallycon-
trolled by an array of mitogenic factors in a temporospatial
order. With advancing gestation, pulmonary vessels acquire
increased vasoreactivity. The fetal pulmonary vasculature is
exposed to a low oxygen tension environment that promotes
high intrinsic myogenic tone and high vasocontractility. At
birth, a dramatic reduction in pulmonary arterial pressure
and resistance occurs with an increase in oxygen tension
and blood ﬂow. The striking hemodynamic diﬀerences in
the pulmonary circulation of the fetus and newborn are
regulated by various factors and vasoactive agents. Among
them, nitric oxide, endothelin-1, and prostaglandin I(2)
are mainly derived from endothelial cells and exert their
eﬀects via cGMP, cAMP, and Rho kinase signalling pathways.
Alterations in these signalling pathways may lead to vascular
remodelling, high vasocontractility, and PPHN [7, 8].
In this study we were able to document PPHN in 16
preterm neonates, including one with30 weeks of gestational
age with a congenital sepsis and pneumonia. It is already
knownthatthemechanismsthatcouldleadtoPHarealready
presentinthehumanfetusby31weeksofgestation[5,9,10].
InourpatientsweobservedahighnumberofC-sectionsthat
are related to prenatal diagnosis of pulmonary hypoplasia,
as congenital diaphragmatic hernias, Potter syndrome, or
meconium-stained amniotic ﬂuid.
The most common cause of PPHN in this study was pul-
monary hypoplasia. Congenital diaphragmatic hernia was
the most prevalent cause of pulmonary hypoplasia. Congen-
ital diaphragmatic hernia and oligohydramnios secondary to
renal anomalies or premature rupture of membranes leads
to pulmonary hypoplasia. Pulmonary hypertension often
occurs as a complication because of the decreased number
of blood vessels and increased reactivity of the vessels in
the hypoplastic lungs. PPHN is usually more chronic and
less responsive to vasodilator therapy in these infants and
their outcome is related to the degree of lung hypoplasia,
associated anomalies, as well as lengt of pulmonary hyper-
tension [11]. The outcome for neonates who have congenital
diaphragmatic hernia has improved since gentle ventilation
and permissive hypercapnia have been incorporated into the
management, with many centers reporting 75% survival in
recent years [11, 12]. The survival of patients with congenital
diaphragmatic hernia has improved in our center since 2003,
a n di sn o w a d a y so v e r6 1 %[ 13].
The second cause of PPHN in this study was congenital
pneumoniaandsepsis.PPHNcanbeacomplicationofpneu-
monia or sepsis secondary to common neonatal pathogens
[14]. Bacterial endotoxin causes pulmonary hypertension
fromseveralmechanisms,includingthereleaseofthrombox-
ane, endothelin, and several cytokines [15, 16]. Sepsis also
leads to systemic hypotension from activation of inducible
nitric oxide synthase with excess nitric oxide release in the
systemic vascular beds, impaired myocardial function, and
multiorgan failure. Addressing PH should be a component
of the overall management of septic shock and prevention of
multiorgan failure in the aﬀected neonates.
Another signiﬁcant group of causes of PPHN were
the aspiration syndromes, mainly meconium aspiration
syndrome, representing 12.8% of PPHN in this series.
Although meconium staining of amniotic ﬂuid occurs in
10% to 15% of pregnancies, meconium aspiration syndrome4 Pulmonary Medicine
Table 4: Survival rates between two periods.
1996–2002 2003–2010 P
n = 36 n = 42
Gestational age, weeks, median (min–max) 41 (30–41) 39 (32–41) 0.032§
Preterm (<37 weeks of gestation), n (%) 8 (22) 8 (19) 0.081∗
Birthweigt, g, median (min–max) 3100 (1450–4170) 3040 (1800–4070) 0.354§
Gender
Male, n (%) 23 (64) 30 (71)
Female, n (%) 13 (36) 12 (29) 0.456∗
C-section, n (%) 23 (64) 28 (67) 0.657∗
Outborn, n (%) 18 (50) 16 (38) 0.071∗
NICU stay 10 (1–67) 16 (1–167) 0.034§
Time to normalization of PH 5 (2–25) 9 (2–160) 0.0391§
Survival, n (%) 23 (63.8)% 30 (71.4) 0.040∗∗
§: Mann-Whitney test; ∗: Chi-Squared test; ∗∗: Fisher Exact test; NICU: neonatal intensive care unit; PH; pulmonary hypertension.
occurs infrequently, in up to 5% of neonates born through
meconium stained ﬂuid. The incidence of meconium aspi-
ration syndrome has declined in recent years [17]w i t h
decreasing postterm pregnancies. This observation suggests
that meconium aspiration syndrome is often a result of in
utero stress with aspiration of meconium by a compromised
fetus. Meconium can cause respiratory failure from several
mechanisms. Meconium can cause mechanical obstruction
to the airways, particularly during exhalation, resulting in
air trapping, hyperinﬂation, and increased risk for pneu-
mothorax.Meconiumcomponentsalsoinactivatesurfactant,
[18] trigger an inﬂammatory response with release of
cytokines, and increase the production of the vasoconstritors
endothelin and thromboxane [19]. Recent advances in the
management of PPHN have resulted in an excellent outcome
for neonates who have meconium aspiration syndrome [20].
InthisstudyPPHNoccurredasacomplicationofhyaline
membrane disease and transient tachypnea of the preterm
newborn, often delivered by C-section, at 34–37 week’s of
gestation. The increasing reactivity of pulmonary arteries at
this gestation period predisposes these neonates to PH when
gas exchange is impaired because of surfactant deﬁciency
[21].
The association of PPHN with maternal intake of non-
steroid anti-inﬂammatory drugs as indomethacin has been
recognizedincasereportssince1970[22,23].Astrongcausal
association is also suggested by the consistent reproduction
of hemodynamic and structural features of PPHN by fetal
ductal constriction [24, 25].
Maldevelopment of pulmonary arteries (pulmonary
“arteriopathy” and idiopathic pulmonary arteriolar calci-
ﬁcation) and thrombosis of pulmonary arteries (probably
associated to coagulation disorders that were not assessed)
were necropsy ﬁndings in three patients without any evident
cause for the PH on clinical grounds. Maladaptation of
the pulmonary vascular bed in asphyxia, maternal diabetes,
and fetal tachyarrhythmia were also identiﬁed in this study,
as well as in two patients with malformation of vein of
Galeno and PPHN associated to high cardiac output failure
from large arteriovenous malformations. These causes of
PPHN have already been described [26]. The cases of PPHN
of unknown aetiology in this series were transient forms
with a good outcome, suggesting transient maladaptation to
extrauterine life.
Neonates who have PPHN require supportive care tai-
lored to the degree of hypoxemia and physiologic instability.
Oxygen is a potent vasodilator and was used in all patients,
once hypoxemia is usually present. Mechanical ventilation
facilitates alveolar recruitment and lung expansion, poten-
tially improving the ventilation/perfusion (V/Q) match. In
this study, mechanical ventilation was used in all, except in
four cases of transient tachypnea of the newborn and three
cases of PPHN of unknown aetiology with mild pulmonary
hypertension. Surfactant has been shown to decrease the
needforECMOinfull-termneonateswithsevererespiratory
failure [27]. The beneﬁcial eﬀe c to fs u r f a c t a n ti nt h i s
study was seen particularly in babies who had meconium
aspiration syndrome and sepsis. Sedatives, although widely
used to minimize ﬂuctuations in oxygenation and facilitate
ventilation,havenotbeentestedinrandomizedtrials[5].We
have used sedatives in all ventilated patients to ameliorate
oxygenation and to decrease discomfort. We do not use for
routine skeletal muscle relaxants. Inotropic and vasopressor
support with dopamine, dobutamine, and epinephrine is
used to optimize cardiac function, stabilize systemic blood
pressure, and decrease right-to-left shunt. From 2003 we
have used iNO and sildenaﬁl, in selected cases of severe
PPHN, mainly in congenital diaphragmatic hernia. Both the
survival rate of congenital diaphragmatic hernia and all cases
of PPHN showed a signiﬁcant increase since 2003. ECMO
has signiﬁcantly improved the survival of neonates with
severe but reversible lung disease [28, 29], but we do not
have experience on that. We tried ECMO in a poor prognosis
for of bilateral congenital diaphragmatic hernia with severe
pulmonary hypoplasia and pulmonary hypertension, but the
patient did not survive.
The overall survival rate described in the literature,
including all causes of PPHN, is over 70–75% [30]. Our
results are now according to these ﬁgures. There is, however,
am a r k e dd i ﬀerence depending on the underlying disease.
There are also signiﬁcant diﬀerences in long-term outcome
according to the cause of PPHN.Pulmonary Medicine 5
This study is limited by the fact of being a single center
retrospective analysis, including a small sample of some rare
pulmonary disorders causing PH. Prospective studies with
the objective of evaluating the diﬀerent therapies in the
various groups of underlying diseases, including a signiﬁcant
number of patients, will give much more information
regarding therapeutic eﬃcacy and survival.
Future research must address the diﬀerent causes of
PPHN and therapies separately, in large multicenter studies.
In conclusion, our study shows a myriad of non cardiac
aetiologies for PPHN, most of them related to lung disease
or lung hypoplasia. We observed an improvement in survival
rate since 2003, and we believe that this is related to the use
of new therapies. We hope that ECMO will oﬀer additional
advantages at our NICU for selected infants in the near
future.
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